File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clarithromycin attenuates cyclophosphamide-induced mucositis in mice

TitleClarithromycin attenuates cyclophosphamide-induced mucositis in mice
Authors
Issue Date2000
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/issn/10436618
Citation
Pharmacological Research, 2000, v. 41 n. 5, p. 527-532 How to Cite?
AbstractNo universally recognized agent is available for prophylaxis or therapy of mucositis induced by chemotherapy or chemo-radiotherapy. The effect of clarithromycin on the severity of mucositis induced by cyclophosphamide was investigated using a mouse model. Four cross-sections of small intestine (levels A, B, C, and D) were taken at equivalent intervals at day 5 after cyclophosphamide (400 mg kg-1) administration. The sections were stained with haematoxylin and eosin, and were graded for the degree of mucositis histologically. At section level B, the number of mice with no mucositis (grade 0) in the clarithromycin group was significantly greater than that in the ceftriaxone group (P < 0.05). At levels B and C, the number of mice with no mucositis (grade 0) in the clarithromycin group was significantly greater than that in the normal saline (NS) group (P < 0.05). At level C, the number of mice with grade 2 mucositis in the ceftriaxone group was significantly greater than that in the NS group (P < 0.05). When the number of sections at all levels were analyzed together, the number of mice with no mucositis (grade 0) in the clarithromycin group was significantly greater than that in the ceftriaxone and NS groups (P < 0.05). The present observation suggests that clarithromycin and ceftriaxone attenuates and aggravates cyclophosphamide-induced mucositis. It prompts clinical trials in bone marrow transplant (BMT) recipients receiving cyclophosphamide for conditioning, and reconsideration in the use of ceftriaxone in the treatment of neutropenic fever in BMT recipients. (C) 2000 Academic Press.
Persistent Identifierhttp://hdl.handle.net/10722/78941
ISSN
2015 Impact Factor: 4.816
2015 SCImago Journal Rankings: 2.108
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWoo, PCYen_HK
dc.contributor.authorNg, WFen_HK
dc.contributor.authorLeung, HCHen_HK
dc.contributor.authorTsoi, HWen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2010-09-06T07:48:40Z-
dc.date.available2010-09-06T07:48:40Z-
dc.date.issued2000en_HK
dc.identifier.citationPharmacological Research, 2000, v. 41 n. 5, p. 527-532en_HK
dc.identifier.issn1043-6618en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78941-
dc.description.abstractNo universally recognized agent is available for prophylaxis or therapy of mucositis induced by chemotherapy or chemo-radiotherapy. The effect of clarithromycin on the severity of mucositis induced by cyclophosphamide was investigated using a mouse model. Four cross-sections of small intestine (levels A, B, C, and D) were taken at equivalent intervals at day 5 after cyclophosphamide (400 mg kg-1) administration. The sections were stained with haematoxylin and eosin, and were graded for the degree of mucositis histologically. At section level B, the number of mice with no mucositis (grade 0) in the clarithromycin group was significantly greater than that in the ceftriaxone group (P < 0.05). At levels B and C, the number of mice with no mucositis (grade 0) in the clarithromycin group was significantly greater than that in the normal saline (NS) group (P < 0.05). At level C, the number of mice with grade 2 mucositis in the ceftriaxone group was significantly greater than that in the NS group (P < 0.05). When the number of sections at all levels were analyzed together, the number of mice with no mucositis (grade 0) in the clarithromycin group was significantly greater than that in the ceftriaxone and NS groups (P < 0.05). The present observation suggests that clarithromycin and ceftriaxone attenuates and aggravates cyclophosphamide-induced mucositis. It prompts clinical trials in bone marrow transplant (BMT) recipients receiving cyclophosphamide for conditioning, and reconsideration in the use of ceftriaxone in the treatment of neutropenic fever in BMT recipients. (C) 2000 Academic Press.en_HK
dc.languageengen_HK
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/issn/10436618en_HK
dc.relation.ispartofPharmacological Researchen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAnti-Bacterial Agents - pharmacologyen_HK
dc.subject.meshAntineoplastic Agents, Alkylating - toxicityen_HK
dc.subject.meshCeftriaxone - therapeutic useen_HK
dc.subject.meshClarithromycin - pharmacologyen_HK
dc.subject.meshCyclophosphamide - toxicityen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshInflammation - prevention & controlen_HK
dc.subject.meshIntestinal Mucosa - drug effectsen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred BALB Cen_HK
dc.titleClarithromycin attenuates cyclophosphamide-induced mucositis in miceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1043-6618&volume=41&issue=5&spage=527&epage=532&date=2000&atitle=Clarithromycin+attenuates+cyclophosphamide-induced+mucositis+in+miceen_HK
dc.identifier.emailWoo, PCY:pcywoo@hkucc.hku.hken_HK
dc.identifier.emailTsoi, HW:hwtsoi@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityWoo, PCY=rp00430en_HK
dc.identifier.authorityTsoi, HW=rp00439en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1006/phrs.1999.0613en_HK
dc.identifier.pmid10753551-
dc.identifier.scopuseid_2-s2.0-0033840021en_HK
dc.identifier.hkuros61792en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033840021&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume41en_HK
dc.identifier.issue5en_HK
dc.identifier.spage527en_HK
dc.identifier.epage532en_HK
dc.identifier.isiWOS:000086601500004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWoo, PCY=7201801340en_HK
dc.identifier.scopusauthoridNg, WF=36787044800en_HK
dc.identifier.scopusauthoridLeung, HCH=36755846800en_HK
dc.identifier.scopusauthoridTsoi, HW=6603822102en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats